AVANT Immunotherapeutics Appoints Peter Sears to Board of Directors

Strategic Insights -

Peter Sears, a renowned expert in corporate investing and venture capital, has joined the board of directors of AVANT Immunotherapeutics, Inc. Sears has an impressive track record of investing in emerging biomedical companies, with S.R. One, the venture capital fund he founded in 1985, investing nearly a quarter of a billion dollars in such ventures. His expertise will be invaluable to AVANT, particularly in the realm of corporate partnering, as the company navigates its next stage of development.

Key Takeaways:

  • Peter Sears, a seasoned investor and entrepreneur, has joined the board of directors of AVANT Immunotherapeutics, Inc.
  • Sears brings extensive experience in corporate investing, having founded S.R. One in 1985, which has invested nearly a quarter of a billion dollars in emerging biomedical companies.
  • Sears' appointment is expected to provide valuable insights for AVANT, particularly in areas such as corporate partnering and product development.
  • Sears has a long history of achievements, including serving as Vice President, Business Investments at SmithKline Beecham Corporation, and as a Director for several companies, including Alere, Inc., and Gryphon Sciences.
  • AVANT Immunotherapeutics is engaged in developing products that harness the human immune response to prevent and treat disease, with its lead therapeutic program focused on compounds that inhibit the complement cascade.

Statistics:

  • S.R. One, the venture capital fund founded by Peter Sears, has invested nearly a quarter of a billion dollars in emerging biomedical companies.
  • AVANT Immunotherapeutics has a lead therapeutic program focused on compounds that inhibit the complement cascade, a vital part of the body's immune defense system.
  • The Company is also developing Therapore, a novel system for the delivery of immunotherapeutics for chronic viral infections and certain cancers.
  • AVANT has collaborations in place with other companies to develop vaccines against diseases such as rotavirus and atherosclerosis.

Sources:

  • AVANT Immunotherapeutics, Inc. press release, May 6 (no specific publication date or timestamp mentioned)
  • AVANT Immunotherapeutics, Inc. website, http://www.avantimmune.com
  • SmithKline Beecham Corporation, S.R. One Limited press release (no specific publication date or timestamp mentioned)
  • Private Securities Litigation Reform Act of 1995
  • Securities and Exchange Commission filings (no specific citation or date mentioned)